OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website. London and New York, NY

Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website.

and New York, NY, March 16, 2023 - OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company

which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market,

today announced that its planned trial evaluating the efficacy and safety of OK-101 in subjects with DED has been posted on the ClinicalTrials.gov

public website (ClinicalTrials.gov Identifier: NCT05759208). ClinicalTrials.gov is a Web-based resource that provides patients, their

family members, health care professionals, researchers, and the public with easy access to information on publicly and privately supported

clinical studies on a wide range of diseases and conditions.

is presently in the process of activating those clinical sites planned for the trial, and preparing the clinical trial drug product OK-101

for shipment to those sites involved in the double-blind, placebo-controlled trial, along with other activities needed for initiating

the trial. OKYO is now anticipating the first-patient first-visit initiation of the trial in early Q2 2023 and still looking to release

top-line data from this trial in Q4 2023.

are excited to be very close now to moving this drug into its first clinical trial and believe that OK-101 can provide a new way to treat

DED patients who are presently not well-served by currently approved drugs" said Gary S. Jacob, Ph.D., CEO of OKYO Pharma Ltd.

Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences company admitted to listing on NASDAQ and on the standard segment of the

Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange

plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain. For

further information, please visit www.okyopharma.com.

is a lipid conjugated chemerin peptide antagonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells

of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide (MAP) technology to produce

a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing

activities in mouse models of dry eye disease and corneal neuropathic pain; and is designed to combat washout through the inclusion of

the lipid anchor' contained in the candidate drug molecule to enhance the residence time of OK-101 within the ocular environment.

statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather

are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words

such as anticipates,' expects,' intends,' plans,' believes,' seeks,'

estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees

of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's

control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking

statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking

statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this

announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to

release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events

occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

further information, please visit the Company's website at www.okyopharma.com

person who arranged for the release of this announcement on behalf of the Company was Gary S. Jacob, Ph.D., Chief Executive Officer of